Manage subscriptions   |   FAQ   |   Report Bugs/Errors/Omissions to ors@sfu.ca
7 entries found

Alzheimer's Drug Discovery Foundation (US)

Filter By:
  • Topic
  • Deadline
  • Region
Sort By:
  • Title
  • Deadline
  • Maximum Award

Sorry, no opportunities were found, please adjust your filters or try another search

20220711

Alzheimer Society Research Program (Proof of Concept) Canadian 11 11 days until deadline

Deadline: July 11, 2022*
*NOTE: This deadline is an estimate based on previous years, but a confirmed deadline has not yet been published. We will update the deadline when it has been confirmed.

The Proof of Concept Grant provides $100,000 over up to 3 years to support investigators with innovative, high-risk, high-yield hypotheses about dementia. The Alzheimer Society Research Program will pre-screen applications for the Proof of Concept Grant through a Letter of Intent (LOI) process. Successful LOI applicants will then be asked to submit a full application for peer review later in the summer.

20220718
600000

ADDF-Harrington Scholar Program International Verified Date 18 18 days until deadline

Deadline: July 18, 2022
Maximum Award: $600,000 CAD

This year's RFP seeks programs that focus on all novel approaches for Alzheimer’s disease and related dementias, with a particular emphasis on the areas of proteostasis and epigenetics. It provides up to $600,000 of funding support for two years.

20220722

Core Funding Programs International Verified Date 22 22 days until deadline

Deadline: July 22, 2022

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. NOTE: This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. We have dedicated our funding to several key areas: - Translational research to develop new drugs and build preclinical evidence - IND-enabling studies and early-stage clinical trials for novel and repurposed drugs - Development and validation of plasma, CSF, neuroimaging and digital biomarkers - Epidemiological studies and comparative effectiveness research

20220930

Core Funding Programs International Verified Date

Deadline: September 30, 2022

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. NOTE: This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. We have dedicated our funding to several key areas: - Translational research to develop new drugs and build preclinical evidence - IND-enabling studies and early-stage clinical trials for novel and repurposed drugs - Development and validation of plasma, CSF, neuroimaging and digital biomarkers - Epidemiological studies and comparative effectiveness research

20221202

Core Funding Programs International Verified Date

Deadline: December 02, 2022

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. NOTE: This funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones. We have dedicated our funding to several key areas: - Translational research to develop new drugs and build preclinical evidence - IND-enabling studies and early-stage clinical trials for novel and repurposed drugs - Development and validation of plasma, CSF, neuroimaging and digital biomarkers - Epidemiological studies and comparative effectiveness research

20230520
100000

Accelerating Drug Discovery for Frontotemporal Degeneration RFP International

Deadline: May 20, 2023*
*NOTE: This deadline is an estimate based on previous years, but a confirmed deadline has not yet been published. We will update the deadline when it has been confirmed.
Maximum Award: $100,000 USD

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD) jointly announce that the Accelerating Drug Discovery for Frontotemporal Degeneration RFP is now accepting letters of intent. This RFP supports innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug development programs for frontotemporal dementia (FTD).

99991231

Diagnostic Accelerator International Verified Date

Deadline: TBD

The Diagnostics Accelerator challenges the research community to develop cutting-edge biomarkers and explore novel diagnostic technologies that will aid in Alzheimer’s diagnosis and clinical trial design. Research funded to date focuses on various methods and targets including blood tests in various stages of development, as well as eye scans and digital tools.


x